000088209512/312023Q3falseP3M00008820952023-01-012023-09-3000008820952023-10-31xbrli:shares00008820952023-09-30iso4217:USD00008820952022-12-31iso4217:USDxbrli:shares0000882095us-gaap:ProductMember2023-07-012023-09-300000882095us-gaap:ProductMember2022-07-012022-09-300000882095us-gaap:ProductMember2023-01-012023-09-300000882095us-gaap:ProductMember2022-01-012022-09-300000882095gild:RoyaltyContractAndOtherMember2023-07-012023-09-300000882095gild:RoyaltyContractAndOtherMember2022-07-012022-09-300000882095gild:RoyaltyContractAndOtherMember2023-01-012023-09-300000882095gild:RoyaltyContractAndOtherMember2022-01-012022-09-3000008820952023-07-012023-09-3000008820952022-07-012022-09-3000008820952022-01-012022-09-300000882095us-gaap:CommonStockMember2023-06-300000882095us-gaap:AdditionalPaidInCapitalMember2023-06-300000882095us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000882095us-gaap:RetainedEarningsMember2023-06-300000882095us-gaap:NoncontrollingInterestMember2023-06-3000008820952023-06-300000882095us-gaap:RetainedEarningsMember2023-07-012023-09-300000882095us-gaap:NoncontrollingInterestMember2023-07-012023-09-300000882095us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000882095us-gaap:CommonStockMember2023-07-012023-09-300000882095us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000882095us-gaap:CommonStockMember2023-09-300000882095us-gaap:AdditionalPaidInCapitalMember2023-09-300000882095us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000882095us-gaap:RetainedEarningsMember2023-09-300000882095us-gaap:NoncontrollingInterestMember2023-09-300000882095us-gaap:CommonStockMember2022-12-310000882095us-gaap:AdditionalPaidInCapitalMember2022-12-310000882095us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000882095us-gaap:RetainedEarningsMember2022-12-310000882095us-gaap:NoncontrollingInterestMember2022-12-310000882095us-gaap:RetainedEarningsMember2023-01-012023-09-300000882095us-gaap:NoncontrollingInterestMember2023-01-012023-09-300000882095us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000882095us-gaap:CommonStockMember2023-01-012023-09-300000882095us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300000882095us-gaap:CommonStockMember2022-06-300000882095us-gaap:AdditionalPaidInCapitalMember2022-06-300000882095us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000882095us-gaap:RetainedEarningsMember2022-06-300000882095us-gaap:NoncontrollingInterestMember2022-06-3000008820952022-06-300000882095us-gaap:RetainedEarningsMember2022-07-012022-09-300000882095us-gaap:NoncontrollingInterestMember2022-07-012022-09-300000882095us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000882095us-gaap:CommonStockMember2022-07-012022-09-300000882095us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300000882095us-gaap:CommonStockMember2022-09-300000882095us-gaap:AdditionalPaidInCapitalMember2022-09-300000882095us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300000882095us-gaap:RetainedEarningsMember2022-09-300000882095us-gaap:NoncontrollingInterestMember2022-09-3000008820952022-09-300000882095us-gaap:CommonStockMember2021-12-310000882095us-gaap:AdditionalPaidInCapitalMember2021-12-310000882095us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000882095us-gaap:RetainedEarningsMember2021-12-310000882095us-gaap:NoncontrollingInterestMember2021-12-3100008820952021-12-310000882095us-gaap:RetainedEarningsMember2022-01-012022-09-300000882095us-gaap:NoncontrollingInterestMember2022-01-012022-09-300000882095us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300000882095us-gaap:CommonStockMember2022-01-012022-09-300000882095us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300000882095srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2022-01-012022-09-300000882095gild:HIVProductsBiktarvyMembercountry:US2023-07-012023-09-300000882095srt:EuropeMembergild:HIVProductsBiktarvyMember2023-07-012023-09-300000882095gild:HIVProductsBiktarvyMembergild:OtherInternationalMember2023-07-012023-09-300000882095gild:HIVProductsBiktarvyMember2023-07-012023-09-300000882095gild:HIVProductsBiktarvyMembercountry:US2022-07-012022-09-300000882095srt:EuropeMembergild:HIVProductsBiktarvyMember2022-07-012022-09-300000882095gild:HIVProductsBiktarvyMembergild:OtherInternationalMember2022-07-012022-09-300000882095gild:HIVProductsBiktarvyMember2022-07-012022-09-300000882095gild:HIVProductsCompleraEvipleraMembercountry:US2023-07-012023-09-300000882095srt:EuropeMembergild:HIVProductsCompleraEvipleraMember2023-07-012023-09-300000882095gild:HIVProductsCompleraEvipleraMembergild:OtherInternationalMember2023-07-012023-09-300000882095gild:HIVProductsCompleraEvipleraMember2023-07-012023-09-300000882095gild:HIVProductsCompleraEvipleraMembercountry:US2022-07-012022-09-300000882095srt:EuropeMembergild:HIVProductsCompleraEvipleraMember2022-07-012022-09-300000882095gild:HIVProductsCompleraEvipleraMembergild:OtherInternationalMember2022-07-012022-09-300000882095gild:HIVProductsCompleraEvipleraMember2022-07-012022-09-300000882095country:USgild:HIVProductsDescovyMember2023-07-012023-09-300000882095srt:EuropeMembergild:HIVProductsDescovyMember2023-07-012023-09-300000882095gild:HIVProductsDescovyMembergild:OtherInternationalMember2023-07-012023-09-300000882095gild:HIVProductsDescovyMember2023-07-012023-09-300000882095country:USgild:HIVProductsDescovyMember2022-07-012022-09-300000882095srt:EuropeMembergild:HIVProductsDescovyMember2022-07-012022-09-300000882095gild:HIVProductsDescovyMembergild:OtherInternationalMember2022-07-012022-09-300000882095gild:HIVProductsDescovyMember2022-07-012022-09-300000882095gild:HIVProductsGenvoyaMembercountry:US2023-07-012023-09-300000882095srt:EuropeMembergild:HIVProductsGenvoyaMember2023-07-012023-09-300000882095gild:HIVProductsGenvoyaMembergild:OtherInternationalMember2023-07-012023-09-300000882095gild:HIVProductsGenvoyaMember2023-07-012023-09-300000882095gild:HIVProductsGenvoyaMembercountry:US2022-07-012022-09-300000882095srt:EuropeMembergild:HIVProductsGenvoyaMember2022-07-012022-09-300000882095gild:HIVProductsGenvoyaMembergild:OtherInternationalMember2022-07-012022-09-300000882095gild:HIVProductsGenvoyaMember2022-07-012022-09-300000882095country:USgild:HIVProductsOdefseyMember2023-07-012023-09-300000882095srt:EuropeMembergild:HIVProductsOdefseyMember2023-07-012023-09-300000882095gild:HIVProductsOdefseyMembergild:OtherInternationalMember2023-07-012023-09-300000882095gild:HIVProductsOdefseyMember2023-07-012023-09-300000882095country:USgild:HIVProductsOdefseyMember2022-07-012022-09-300000882095srt:EuropeMembergild:HIVProductsOdefseyMember2022-07-012022-09-300000882095gild:HIVProductsOdefseyMembergild:OtherInternationalMember2022-07-012022-09-300000882095gild:HIVProductsOdefseyMember2022-07-012022-09-300000882095country:USgild:HIVProductsStribildMember2023-07-012023-09-300000882095srt:EuropeMembergild:HIVProductsStribildMember2023-07-012023-09-300000882095gild:HIVProductsStribildMembergild:OtherInternationalMember2023-07-012023-09-300000882095gild:HIVProductsStribildMember2023-07-012023-09-300000882095country:USgild:HIVProductsStribildMember2022-07-012022-09-300000882095srt:EuropeMembergild:HIVProductsStribildMember2022-07-012022-09-300000882095gild:HIVProductsStribildMembergild:OtherInternationalMember2022-07-012022-09-300000882095gild:HIVProductsStribildMember2022-07-012022-09-300000882095country:USgild:HIVProductsTruvadaMember2023-07-012023-09-300000882095srt:EuropeMembergild:HIVProductsTruvadaMember2023-07-012023-09-300000882095gild:HIVProductsTruvadaMembergild:OtherInternationalMember2023-07-012023-09-300000882095gild:HIVProductsTruvadaMember2023-07-012023-09-300000882095country:USgild:HIVProductsTruvadaMember2022-07-012022-09-300000882095srt:EuropeMembergild:HIVProductsTruvadaMember2022-07-012022-09-300000882095gild:HIVProductsTruvadaMembergild:OtherInternationalMember2022-07-012022-09-300000882095gild:HIVProductsTruvadaMember2022-07-012022-09-300000882095gild:ProductsRevenueShareSymtuzaMembercountry:US2023-07-012023-09-300000882095srt:EuropeMembergild:ProductsRevenueShareSymtuzaMember2023-07-012023-09-300000882095gild:ProductsRevenueShareSymtuzaMembergild:OtherInternationalMember2023-07-012023-09-300000882095gild:ProductsRevenueShareSymtuzaMember2023-07-012023-09-300000882095gild:ProductsRevenueShareSymtuzaMembercountry:US2022-07-012022-09-300000882095srt:EuropeMembergild:ProductsRevenueShareSymtuzaMember2022-07-012022-09-300000882095gild:ProductsRevenueShareSymtuzaMembergild:OtherInternationalMember2022-07-012022-09-300000882095gild:ProductsRevenueShareSymtuzaMember2022-07-012022-09-300000882095gild:ProductsOtherHIVMembercountry:US2023-07-012023-09-300000882095srt:EuropeMembergild:ProductsOtherHIVMember2023-07-012023-09-300000882095gild:ProductsOtherHIVMembergild:OtherInternationalMember2023-07-012023-09-300000882095gild:ProductsOtherHIVMember2023-07-012023-09-300000882095gild:ProductsOtherHIVMembercountry:US2022-07-012022-09-300000882095srt:EuropeMembergild:ProductsOtherHIVMember2022-07-012022-09-300000882095gild:ProductsOtherHIVMembergild:OtherInternationalMember2022-07-012022-09-300000882095gild:ProductsOtherHIVMember2022-07-012022-09-300000882095country:USgild:HIVProductSalesMember2023-07-012023-09-300000882095srt:EuropeMembergild:HIVProductSalesMember2023-07-012023-09-300000882095gild:HIVProductSalesMembergild:OtherInternationalMember2023-07-012023-09-300000882095gild:HIVProductSalesMember2023-07-012023-09-300000882095country:USgild:HIVProductSalesMember2022-07-012022-09-300000882095srt:EuropeMembergild:HIVProductSalesMember2022-07-012022-09-300000882095gild:HIVProductSalesMembergild:OtherInternationalMember2022-07-012022-09-300000882095gild:HIVProductSalesMember2022-07-012022-09-300000882095gild:CellTherapyProductsTecartusMembercountry:US2023-07-012023-09-300000882095srt:EuropeMembergild:CellTherapyProductsTecartusMember2023-07-012023-09-300000882095gild:CellTherapyProductsTecartusMembergild:OtherInternationalMember2023-07-012023-09-300000882095gild:CellTherapyProductsTecartusMember2023-07-012023-09-300000882095gild:CellTherapyProductsTecartusMembercountry:US2022-07-012022-09-300000882095srt:EuropeMembergild:CellTherapyProductsTecartusMember2022-07-012022-09-300000882095gild:CellTherapyProductsTecartusMembergild:OtherInternationalMember2022-07-012022-09-300000882095gild:CellTherapyProductsTecartusMember2022-07-012022-09-300000882095gild:CellTherapyProductsYescartaMembercountry:US2023-07-012023-09-300000882095srt:EuropeMembergild:CellTherapyProductsYescartaMember2023-07-012023-09-300000882095gild:CellTherapyProductsYescartaMembergild:OtherInternationalMember2023-07-012023-09-300000882095gild:CellTherapyProductsYescartaMember2023-07-012023-09-300000882095gild:CellTherapyProductsYescartaMembercountry:US2022-07-012022-09-300000882095srt:EuropeMembergild:CellTherapyProductsYescartaMember2022-07-012022-09-300000882095gild:CellTherapyProductsYescartaMembergild:OtherInternationalMember2022-07-012022-09-300000882095gild:CellTherapyProductsYescartaMember2022-07-012022-09-300000882095gild:CellTherapyProductsTotalCellTherapyProductSalesMembercountry:US2023-07-012023-09-300000882095srt:EuropeMembergild:CellTherapyProductsTotalCellTherapyProductSalesMember2023-07-012023-09-300000882095gild:CellTherapyProductsTotalCellTherapyProductSalesMembergild:OtherInternationalMember2023-07-012023-09-300000882095gild:CellTherapyProductsTotalCellTherapyProductSalesMember2023-07-012023-09-300000882095gild:CellTherapyProductsTotalCellTherapyProductSalesMembercountry:US2022-07-012022-09-300000882095srt:EuropeMembergild:CellTherapyProductsTotalCellTherapyProductSalesMember2022-07-012022-09-300000882095gild:CellTherapyProductsTotalCellTherapyProductSalesMembergild:OtherInternationalMember2022-07-012022-09-300000882095gild:CellTherapyProductsTotalCellTherapyProductSalesMember2022-07-012022-09-300000882095gild:TrodelvyMembercountry:US2023-07-012023-09-300000882095gild:TrodelvyMembersrt:EuropeMember2023-07-012023-09-300000882095gild:TrodelvyMembergild:OtherInternationalMember2023-07-012023-09-300000882095gild:TrodelvyMember2023-07-012023-09-300000882095gild:TrodelvyMembercountry:US2022-07-012022-09-300000882095gild:TrodelvyMembersrt:EuropeMember2022-07-012022-09-300000882095gild:TrodelvyMembergild:OtherInternationalMember2022-07-012022-09-300000882095gild:TrodelvyMember2022-07-012022-09-300000882095gild:OncologyProductMembercountry:US2023-07-012023-09-300000882095srt:EuropeMembergild:OncologyProductMember2023-07-012023-09-300000882095gild:OncologyProductMembergild:OtherInternationalMember2023-07-012023-09-300000882095gild:OncologyProductMember2023-07-012023-09-300000882095gild:OncologyProductMembercountry:US2022-07-012022-09-300000882095srt:EuropeMembergild:OncologyProductMember2022-07-012022-09-300000882095gild:OncologyProductMembergild:OtherInternationalMember2022-07-012022-09-300000882095gild:OncologyProductMember2022-07-012022-09-300000882095country:USgild:HCVProductsLedipasvirSofosbuvirMember2023-07-012023-09-300000882095srt:EuropeMembergild:HCVProductsLedipasvirSofosbuvirMember2023-07-012023-09-300000882095gild:HCVProductsLedipasvirSofosbuvirMembergild:OtherInternationalMember2023-07-012023-09-300000882095gild:HCVProductsLedipasvirSofosbuvirMember2023-07-012023-09-300000882095country:USgild:HCVProductsLedipasvirSofosbuvirMember2022-07-012022-09-300000882095srt:EuropeMembergild:HCVProductsLedipasvirSofosbuvirMember2022-07-012022-09-300000882095gild:HCVProductsLedipasvirSofosbuvirMembergild:OtherInternationalMember2022-07-012022-09-300000882095gild:HCVProductsLedipasvirSofosbuvirMember2022-07-012022-09-300000882095country:USgild:HCVProductsSofosbuvirVelpatasvirMember2023-07-012023-09-300000882095srt:EuropeMembergild:HCVProductsSofosbuvirVelpatasvirMember2023-07-012023-09-300000882095gild:OtherInternationalMembergild:HCVProductsSofosbuvirVelpatasvirMember2023-07-012023-09-300000882095gild:HCVProductsSofosbuvirVelpatasvirMember2023-07-012023-09-300000882095country:USgild:HCVProductsSofosbuvirVelpatasvirMember2022-07-012022-09-300000882095srt:EuropeMembergild:HCVProductsSofosbuvirVelpatasvirMember2022-07-012022-09-300000882095gild:OtherInternationalMembergild:HCVProductsSofosbuvirVelpatasvirMember2022-07-012022-09-300000882095gild:HCVProductsSofosbuvirVelpatasvirMember2022-07-012022-09-300000882095gild:OtherHepatitisCVirusProductsMembercountry:US2023-07-012023-09-300000882095srt:EuropeMembergild:OtherHepatitisCVirusProductsMember2023-07-012023-09-300000882095gild:OtherHepatitisCVirusProductsMembergild:OtherInternationalMember2023-07-012023-09-300000882095gild:OtherHepatitisCVirusProductsMember2023-07-012023-09-300000882095gild:OtherHepatitisCVirusProductsMembercountry:US2022-07-012022-09-300000882095srt:EuropeMembergild:OtherHepatitisCVirusProductsMember2022-07-012022-09-300000882095gild:OtherHepatitisCVirusProductsMembergild:OtherInternationalMember2022-07-012022-09-300000882095gild:OtherHepatitisCVirusProductsMember2022-07-012022-09-300000882095gild:HCVProductSalesMembercountry:US2023-07-012023-09-300000882095gild:HCVProductSalesMembersrt:EuropeMember2023-07-012023-09-300000882095gild:HCVProductSalesMembergild:OtherInternationalMember2023-07-012023-09-300000882095gild:HCVProductSalesMember2023-07-012023-09-300000882095gild:HCVProductSalesMembercountry:US2022-07-012022-09-300000882095gild:HCVProductSalesMembersrt:EuropeMember2022-07-012022-09-300000882095gild:HCVProductSalesMembergild:OtherInternationalMember2022-07-012022-09-300000882095gild:HCVProductSalesMember2022-07-012022-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMembercountry:US2023-07-012023-09-300000882095srt:EuropeMembergild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember2023-07-012023-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMembergild:OtherInternationalMember2023-07-012023-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember2023-07-012023-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMembercountry:US2022-07-012022-09-300000882095srt:EuropeMembergild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember2022-07-012022-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMembergild:OtherInternationalMember2022-07-012022-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember2022-07-012022-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMembercountry:US2023-07-012023-09-300000882095srt:EuropeMembergild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember2023-07-012023-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMembergild:OtherInternationalMember2023-07-012023-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember2023-07-012023-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMembercountry:US2022-07-012022-09-300000882095srt:EuropeMembergild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember2022-07-012022-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMembergild:OtherInternationalMember2022-07-012022-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember2022-07-012022-09-300000882095country:USgild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember2023-07-012023-09-300000882095srt:EuropeMembergild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember2023-07-012023-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMembergild:OtherInternationalMember2023-07-012023-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember2023-07-012023-09-300000882095country:USgild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember2022-07-012022-09-300000882095srt:EuropeMembergild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember2022-07-012022-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMembergild:OtherInternationalMember2022-07-012022-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember2022-07-012022-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductMembercountry:US2023-07-012023-09-300000882095srt:EuropeMembergild:HepatitisBVirusHepatitisDeltaVirusProductMember2023-07-012023-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductMembergild:OtherInternationalMember2023-07-012023-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductMember2023-07-012023-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductMembercountry:US2022-07-012022-09-300000882095srt:EuropeMembergild:HepatitisBVirusHepatitisDeltaVirusProductMember2022-07-012022-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductMembergild:OtherInternationalMember2022-07-012022-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductMember2022-07-012022-09-300000882095country:USgild:LiverDiseaseMember2023-07-012023-09-300000882095srt:EuropeMembergild:LiverDiseaseMember2023-07-012023-09-300000882095gild:OtherInternationalMembergild:LiverDiseaseMember2023-07-012023-09-300000882095gild:LiverDiseaseMember2023-07-012023-09-300000882095country:USgild:LiverDiseaseMember2022-07-012022-09-300000882095srt:EuropeMembergild:LiverDiseaseMember2022-07-012022-09-300000882095gild:OtherInternationalMembergild:LiverDiseaseMember2022-07-012022-09-300000882095gild:LiverDiseaseMember2022-07-012022-09-300000882095gild:VekluryMembercountry:US2023-07-012023-09-300000882095srt:EuropeMembergild:VekluryMember2023-07-012023-09-300000882095gild:VekluryMembergild:OtherInternationalMember2023-07-012023-09-300000882095gild:VekluryMember2023-07-012023-09-300000882095gild:VekluryMembercountry:US2022-07-012022-09-300000882095srt:EuropeMembergild:VekluryMember2022-07-012022-09-300000882095gild:VekluryMembergild:OtherInternationalMember2022-07-012022-09-300000882095gild:VekluryMember2022-07-012022-09-300000882095gild:OtherProductsAmBisomeMembercountry:US2023-07-012023-09-300000882095srt:EuropeMembergild:OtherProductsAmBisomeMember2023-07-012023-09-300000882095gild:OtherProductsAmBisomeMembergild:OtherInternationalMember2023-07-012023-09-300000882095gild:OtherProductsAmBisomeMember2023-07-012023-09-300000882095gild:OtherProductsAmBisomeMembercountry:US2022-07-012022-09-300000882095srt:EuropeMembergild:OtherProductsAmBisomeMember2022-07-012022-09-300000882095gild:OtherProductsAmBisomeMembergild:OtherInternationalMember2022-07-012022-09-300000882095gild:OtherProductsAmBisomeMember2022-07-012022-09-300000882095country:USgild:OtherProductsLetairisMember2023-07-012023-09-300000882095srt:EuropeMembergild:OtherProductsLetairisMember2023-07-012023-09-300000882095gild:OtherProductsLetairisMembergild:OtherInternationalMember2023-07-012023-09-300000882095gild:OtherProductsLetairisMember2023-07-012023-09-300000882095country:USgild:OtherProductsLetairisMember2022-07-012022-09-300000882095srt:EuropeMembergild:OtherProductsLetairisMember2022-07-012022-09-300000882095gild:OtherProductsLetairisMembergild:OtherInternationalMember2022-07-012022-09-300000882095gild:OtherProductsLetairisMember2022-07-012022-09-300000882095country:USgild:OtherProductsOtherMember2023-07-012023-09-300000882095srt:EuropeMembergild:OtherProductsOtherMember2023-07-012023-09-300000882095gild:OtherInternationalMembergild:OtherProductsOtherMember2023-07-012023-09-300000882095gild:OtherProductsOtherMember2023-07-012023-09-300000882095country:USgild:OtherProductsOtherMember2022-07-012022-09-300000882095srt:EuropeMembergild:OtherProductsOtherMember2022-07-012022-09-300000882095gild:OtherInternationalMembergild:OtherProductsOtherMember2022-07-012022-09-300000882095gild:OtherProductsOtherMember2022-07-012022-09-300000882095country:USgild:OtherProductsTotalOtherProductSalesMember2023-07-012023-09-300000882095srt:EuropeMembergild:OtherProductsTotalOtherProductSalesMember2023-07-012023-09-300000882095gild:OtherInternationalMembergild:OtherProductsTotalOtherProductSalesMember2023-07-012023-09-300000882095gild:OtherProductsTotalOtherProductSalesMember2023-07-012023-09-300000882095country:USgild:OtherProductsTotalOtherProductSalesMember2022-07-012022-09-300000882095srt:EuropeMembergild:OtherProductsTotalOtherProductSalesMember2022-07-012022-09-300000882095gild:OtherInternationalMembergild:OtherProductsTotalOtherProductSalesMember2022-07-012022-09-300000882095gild:OtherProductsTotalOtherProductSalesMember2022-07-012022-09-300000882095us-gaap:ProductMembercountry:US2023-07-012023-09-300000882095srt:EuropeMemberus-gaap:ProductMember2023-07-012023-09-300000882095us-gaap:ProductMembergild:OtherInternationalMember2023-07-012023-09-300000882095us-gaap:ProductMembercountry:US2022-07-012022-09-300000882095srt:EuropeMemberus-gaap:ProductMember2022-07-012022-09-300000882095us-gaap:ProductMembergild:OtherInternationalMember2022-07-012022-09-300000882095gild:RoyaltyContractAndOtherMembercountry:US2023-07-012023-09-300000882095srt:EuropeMembergild:RoyaltyContractAndOtherMember2023-07-012023-09-300000882095gild:RoyaltyContractAndOtherMembergild:OtherInternationalMember2023-07-012023-09-300000882095gild:RoyaltyContractAndOtherMembercountry:US2022-07-012022-09-300000882095srt:EuropeMembergild:RoyaltyContractAndOtherMember2022-07-012022-09-300000882095gild:RoyaltyContractAndOtherMembergild:OtherInternationalMember2022-07-012022-09-300000882095country:US2023-07-012023-09-300000882095srt:EuropeMember2023-07-012023-09-300000882095gild:OtherInternationalMember2023-07-012023-09-300000882095country:US2022-07-012022-09-300000882095srt:EuropeMember2022-07-012022-09-300000882095gild:OtherInternationalMember2022-07-012022-09-300000882095gild:HIVProductsBiktarvyMembercountry:US2023-01-012023-09-300000882095srt:EuropeMembergild:HIVProductsBiktarvyMember2023-01-012023-09-300000882095gild:HIVProductsBiktarvyMembergild:OtherInternationalMember2023-01-012023-09-300000882095gild:HIVProductsBiktarvyMember2023-01-012023-09-300000882095gild:HIVProductsBiktarvyMembercountry:US2022-01-012022-09-300000882095srt:EuropeMembergild:HIVProductsBiktarvyMember2022-01-012022-09-300000882095gild:HIVProductsBiktarvyMembergild:OtherInternationalMember2022-01-012022-09-300000882095gild:HIVProductsBiktarvyMember2022-01-012022-09-300000882095gild:HIVProductsCompleraEvipleraMembercountry:US2023-01-012023-09-300000882095srt:EuropeMembergild:HIVProductsCompleraEvipleraMember2023-01-012023-09-300000882095gild:HIVProductsCompleraEvipleraMembergild:OtherInternationalMember2023-01-012023-09-300000882095gild:HIVProductsCompleraEvipleraMember2023-01-012023-09-300000882095gild:HIVProductsCompleraEvipleraMembercountry:US2022-01-012022-09-300000882095srt:EuropeMembergild:HIVProductsCompleraEvipleraMember2022-01-012022-09-300000882095gild:HIVProductsCompleraEvipleraMembergild:OtherInternationalMember2022-01-012022-09-300000882095gild:HIVProductsCompleraEvipleraMember2022-01-012022-09-300000882095country:USgild:HIVProductsDescovyMember2023-01-012023-09-300000882095srt:EuropeMembergild:HIVProductsDescovyMember2023-01-012023-09-300000882095gild:HIVProductsDescovyMembergild:OtherInternationalMember2023-01-012023-09-300000882095gild:HIVProductsDescovyMember2023-01-012023-09-300000882095country:USgild:HIVProductsDescovyMember2022-01-012022-09-300000882095srt:EuropeMembergild:HIVProductsDescovyMember2022-01-012022-09-300000882095gild:HIVProductsDescovyMembergild:OtherInternationalMember2022-01-012022-09-300000882095gild:HIVProductsDescovyMember2022-01-012022-09-300000882095gild:HIVProductsGenvoyaMembercountry:US2023-01-012023-09-300000882095srt:EuropeMembergild:HIVProductsGenvoyaMember2023-01-012023-09-300000882095gild:HIVProductsGenvoyaMembergild:OtherInternationalMember2023-01-012023-09-300000882095gild:HIVProductsGenvoyaMember2023-01-012023-09-300000882095gild:HIVProductsGenvoyaMembercountry:US2022-01-012022-09-300000882095srt:EuropeMembergild:HIVProductsGenvoyaMember2022-01-012022-09-300000882095gild:HIVProductsGenvoyaMembergild:OtherInternationalMember2022-01-012022-09-300000882095gild:HIVProductsGenvoyaMember2022-01-012022-09-300000882095country:USgild:HIVProductsOdefseyMember2023-01-012023-09-300000882095srt:EuropeMembergild:HIVProductsOdefseyMember2023-01-012023-09-300000882095gild:HIVProductsOdefseyMembergild:OtherInternationalMember2023-01-012023-09-300000882095gild:HIVProductsOdefseyMember2023-01-012023-09-300000882095country:USgild:HIVProductsOdefseyMember2022-01-012022-09-300000882095srt:EuropeMembergild:HIVProductsOdefseyMember2022-01-012022-09-300000882095gild:HIVProductsOdefseyMembergild:OtherInternationalMember2022-01-012022-09-300000882095gild:HIVProductsOdefseyMember2022-01-012022-09-300000882095country:USgild:HIVProductsStribildMember2023-01-012023-09-300000882095srt:EuropeMembergild:HIVProductsStribildMember2023-01-012023-09-300000882095gild:HIVProductsStribildMembergild:OtherInternationalMember2023-01-012023-09-300000882095gild:HIVProductsStribildMember2023-01-012023-09-300000882095country:USgild:HIVProductsStribildMember2022-01-012022-09-300000882095srt:EuropeMembergild:HIVProductsStribildMember2022-01-012022-09-300000882095gild:HIVProductsStribildMembergild:OtherInternationalMember2022-01-012022-09-300000882095gild:HIVProductsStribildMember2022-01-012022-09-300000882095country:USgild:HIVProductsTruvadaMember2023-01-012023-09-300000882095srt:EuropeMembergild:HIVProductsTruvadaMember2023-01-012023-09-300000882095gild:HIVProductsTruvadaMembergild:OtherInternationalMember2023-01-012023-09-300000882095gild:HIVProductsTruvadaMember2023-01-012023-09-300000882095country:USgild:HIVProductsTruvadaMember2022-01-012022-09-300000882095srt:EuropeMembergild:HIVProductsTruvadaMember2022-01-012022-09-300000882095gild:HIVProductsTruvadaMembergild:OtherInternationalMember2022-01-012022-09-300000882095gild:HIVProductsTruvadaMember2022-01-012022-09-300000882095gild:ProductsRevenueShareSymtuzaMembercountry:US2023-01-012023-09-300000882095srt:EuropeMembergild:ProductsRevenueShareSymtuzaMember2023-01-012023-09-300000882095gild:ProductsRevenueShareSymtuzaMembergild:OtherInternationalMember2023-01-012023-09-300000882095gild:ProductsRevenueShareSymtuzaMember2023-01-012023-09-300000882095gild:ProductsRevenueShareSymtuzaMembercountry:US2022-01-012022-09-300000882095srt:EuropeMembergild:ProductsRevenueShareSymtuzaMember2022-01-012022-09-300000882095gild:ProductsRevenueShareSymtuzaMembergild:OtherInternationalMember2022-01-012022-09-300000882095gild:ProductsRevenueShareSymtuzaMember2022-01-012022-09-300000882095gild:ProductsOtherHIVMembercountry:US2023-01-012023-09-300000882095srt:EuropeMembergild:ProductsOtherHIVMember2023-01-012023-09-300000882095gild:ProductsOtherHIVMembergild:OtherInternationalMember2023-01-012023-09-300000882095gild:ProductsOtherHIVMember2023-01-012023-09-300000882095gild:ProductsOtherHIVMembercountry:US2022-01-012022-09-300000882095srt:EuropeMembergild:ProductsOtherHIVMember2022-01-012022-09-300000882095gild:ProductsOtherHIVMembergild:OtherInternationalMember2022-01-012022-09-300000882095gild:ProductsOtherHIVMember2022-01-012022-09-300000882095country:USgild:HIVProductSalesMember2023-01-012023-09-300000882095srt:EuropeMembergild:HIVProductSalesMember2023-01-012023-09-300000882095gild:HIVProductSalesMembergild:OtherInternationalMember2023-01-012023-09-300000882095gild:HIVProductSalesMember2023-01-012023-09-300000882095country:USgild:HIVProductSalesMember2022-01-012022-09-300000882095srt:EuropeMembergild:HIVProductSalesMember2022-01-012022-09-300000882095gild:HIVProductSalesMembergild:OtherInternationalMember2022-01-012022-09-300000882095gild:HIVProductSalesMember2022-01-012022-09-300000882095gild:CellTherapyProductsTecartusMembercountry:US2023-01-012023-09-300000882095srt:EuropeMembergild:CellTherapyProductsTecartusMember2023-01-012023-09-300000882095gild:CellTherapyProductsTecartusMembergild:OtherInternationalMember2023-01-012023-09-300000882095gild:CellTherapyProductsTecartusMember2023-01-012023-09-300000882095gild:CellTherapyProductsTecartusMembercountry:US2022-01-012022-09-300000882095srt:EuropeMembergild:CellTherapyProductsTecartusMember2022-01-012022-09-300000882095gild:CellTherapyProductsTecartusMembergild:OtherInternationalMember2022-01-012022-09-300000882095gild:CellTherapyProductsTecartusMember2022-01-012022-09-300000882095gild:CellTherapyProductsYescartaMembercountry:US2023-01-012023-09-300000882095srt:EuropeMembergild:CellTherapyProductsYescartaMember2023-01-012023-09-300000882095gild:CellTherapyProductsYescartaMembergild:OtherInternationalMember2023-01-012023-09-300000882095gild:CellTherapyProductsYescartaMember2023-01-012023-09-300000882095gild:CellTherapyProductsYescartaMembercountry:US2022-01-012022-09-300000882095srt:EuropeMembergild:CellTherapyProductsYescartaMember2022-01-012022-09-300000882095gild:CellTherapyProductsYescartaMembergild:OtherInternationalMember2022-01-012022-09-300000882095gild:CellTherapyProductsYescartaMember2022-01-012022-09-300000882095gild:CellTherapyProductsTotalCellTherapyProductSalesMembercountry:US2023-01-012023-09-300000882095srt:EuropeMembergild:CellTherapyProductsTotalCellTherapyProductSalesMember2023-01-012023-09-300000882095gild:CellTherapyProductsTotalCellTherapyProductSalesMembergild:OtherInternationalMember2023-01-012023-09-300000882095gild:CellTherapyProductsTotalCellTherapyProductSalesMember2023-01-012023-09-300000882095gild:CellTherapyProductsTotalCellTherapyProductSalesMembercountry:US2022-01-012022-09-300000882095srt:EuropeMembergild:CellTherapyProductsTotalCellTherapyProductSalesMember2022-01-012022-09-300000882095gild:CellTherapyProductsTotalCellTherapyProductSalesMembergild:OtherInternationalMember2022-01-012022-09-300000882095gild:CellTherapyProductsTotalCellTherapyProductSalesMember2022-01-012022-09-300000882095gild:TrodelvyMembercountry:US2023-01-012023-09-300000882095gild:TrodelvyMembersrt:EuropeMember2023-01-012023-09-300000882095gild:TrodelvyMembergild:OtherInternationalMember2023-01-012023-09-300000882095gild:TrodelvyMember2023-01-012023-09-300000882095gild:TrodelvyMembercountry:US2022-01-012022-09-300000882095gild:TrodelvyMembersrt:EuropeMember2022-01-012022-09-300000882095gild:TrodelvyMembergild:OtherInternationalMember2022-01-012022-09-300000882095gild:TrodelvyMember2022-01-012022-09-300000882095gild:OncologyProductMembercountry:US2023-01-012023-09-300000882095srt:EuropeMembergild:OncologyProductMember2023-01-012023-09-300000882095gild:OncologyProductMembergild:OtherInternationalMember2023-01-012023-09-300000882095gild:OncologyProductMember2023-01-012023-09-300000882095gild:OncologyProductMembercountry:US2022-01-012022-09-300000882095srt:EuropeMembergild:OncologyProductMember2022-01-012022-09-300000882095gild:OncologyProductMembergild:OtherInternationalMember2022-01-012022-09-300000882095gild:OncologyProductMember2022-01-012022-09-300000882095country:USgild:HCVProductsLedipasvirSofosbuvirMember2023-01-012023-09-300000882095srt:EuropeMembergild:HCVProductsLedipasvirSofosbuvirMember2023-01-012023-09-300000882095gild:HCVProductsLedipasvirSofosbuvirMembergild:OtherInternationalMember2023-01-012023-09-300000882095gild:HCVProductsLedipasvirSofosbuvirMember2023-01-012023-09-300000882095country:USgild:HCVProductsLedipasvirSofosbuvirMember2022-01-012022-09-300000882095srt:EuropeMembergild:HCVProductsLedipasvirSofosbuvirMember2022-01-012022-09-300000882095gild:HCVProductsLedipasvirSofosbuvirMembergild:OtherInternationalMember2022-01-012022-09-300000882095gild:HCVProductsLedipasvirSofosbuvirMember2022-01-012022-09-300000882095country:USgild:HCVProductsSofosbuvirVelpatasvirMember2023-01-012023-09-300000882095srt:EuropeMembergild:HCVProductsSofosbuvirVelpatasvirMember2023-01-012023-09-300000882095gild:OtherInternationalMembergild:HCVProductsSofosbuvirVelpatasvirMember2023-01-012023-09-300000882095gild:HCVProductsSofosbuvirVelpatasvirMember2023-01-012023-09-300000882095country:USgild:HCVProductsSofosbuvirVelpatasvirMember2022-01-012022-09-300000882095srt:EuropeMembergild:HCVProductsSofosbuvirVelpatasvirMember2022-01-012022-09-300000882095gild:OtherInternationalMembergild:HCVProductsSofosbuvirVelpatasvirMember2022-01-012022-09-300000882095gild:HCVProductsSofosbuvirVelpatasvirMember2022-01-012022-09-300000882095gild:OtherHepatitisCVirusProductsMembercountry:US2023-01-012023-09-300000882095srt:EuropeMembergild:OtherHepatitisCVirusProductsMember2023-01-012023-09-300000882095gild:OtherHepatitisCVirusProductsMembergild:OtherInternationalMember2023-01-012023-09-300000882095gild:OtherHepatitisCVirusProductsMember2023-01-012023-09-300000882095gild:OtherHepatitisCVirusProductsMembercountry:US2022-01-012022-09-300000882095srt:EuropeMembergild:OtherHepatitisCVirusProductsMember2022-01-012022-09-300000882095gild:OtherHepatitisCVirusProductsMembergild:OtherInternationalMember2022-01-012022-09-300000882095gild:OtherHepatitisCVirusProductsMember2022-01-012022-09-300000882095gild:HCVProductSalesMembercountry:US2023-01-012023-09-300000882095gild:HCVProductSalesMembersrt:EuropeMember2023-01-012023-09-300000882095gild:HCVProductSalesMembergild:OtherInternationalMember2023-01-012023-09-300000882095gild:HCVProductSalesMember2023-01-012023-09-300000882095gild:HCVProductSalesMembercountry:US2022-01-012022-09-300000882095gild:HCVProductSalesMembersrt:EuropeMember2022-01-012022-09-300000882095gild:HCVProductSalesMembergild:OtherInternationalMember2022-01-012022-09-300000882095gild:HCVProductSalesMember2022-01-012022-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMembercountry:US2023-01-012023-09-300000882095srt:EuropeMembergild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember2023-01-012023-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMembergild:OtherInternationalMember2023-01-012023-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember2023-01-012023-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMembercountry:US2022-01-012022-09-300000882095srt:EuropeMembergild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember2022-01-012022-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMembergild:OtherInternationalMember2022-01-012022-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember2022-01-012022-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMembercountry:US2023-01-012023-09-300000882095srt:EuropeMembergild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember2023-01-012023-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMembergild:OtherInternationalMember2023-01-012023-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember2023-01-012023-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMembercountry:US2022-01-012022-09-300000882095srt:EuropeMembergild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember2022-01-012022-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMembergild:OtherInternationalMember2022-01-012022-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember2022-01-012022-09-300000882095country:USgild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember2023-01-012023-09-300000882095srt:EuropeMembergild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember2023-01-012023-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMembergild:OtherInternationalMember2023-01-012023-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember2023-01-012023-09-300000882095country:USgild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember2022-01-012022-09-300000882095srt:EuropeMembergild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember2022-01-012022-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMembergild:OtherInternationalMember2022-01-012022-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember2022-01-012022-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductMembercountry:US2023-01-012023-09-300000882095srt:EuropeMembergild:HepatitisBVirusHepatitisDeltaVirusProductMember2023-01-012023-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductMembergild:OtherInternationalMember2023-01-012023-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductMember2023-01-012023-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductMembercountry:US2022-01-012022-09-300000882095srt:EuropeMembergild:HepatitisBVirusHepatitisDeltaVirusProductMember2022-01-012022-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductMembergild:OtherInternationalMember2022-01-012022-09-300000882095gild:HepatitisBVirusHepatitisDeltaVirusProductMember2022-01-012022-09-300000882095country:USgild:LiverDiseaseMember2023-01-012023-09-300000882095srt:EuropeMembergild:LiverDiseaseMember2023-01-012023-09-300000882095gild:OtherInternationalMembergild:LiverDiseaseMember2023-01-012023-09-300000882095gild:LiverDiseaseMember2023-01-012023-09-300000882095country:USgild:LiverDiseaseMember2022-01-012022-09-300000882095srt:EuropeMembergild:LiverDiseaseMember2022-01-012022-09-300000882095gild:OtherInternationalMembergild:LiverDiseaseMember2022-01-012022-09-300000882095gild:LiverDiseaseMember2022-01-012022-09-300000882095gild:VekluryMembercountry:US2023-01-012023-09-300000882095srt:EuropeMembergild:VekluryMember2023-01-012023-09-300000882095gild:VekluryMembergild:OtherInternationalMember2023-01-012023-09-300000882095gild:VekluryMember2023-01-012023-09-300000882095gild:VekluryMembercountry:US2022-01-012022-09-300000882095srt:EuropeMembergild:VekluryMember2022-01-012022-09-300000882095gild:VekluryMembergild:OtherInternationalMember2022-01-012022-09-300000882095gild:VekluryMember2022-01-012022-09-300000882095gild:OtherProductsAmBisomeMembercountry:US2023-01-012023-09-300000882095srt:EuropeMembergild:OtherProductsAmBisomeMember2023-01-012023-09-300000882095gild:OtherProductsAmBisomeMembergild:OtherInternationalMember2023-01-012023-09-300000882095gild:OtherProductsAmBisomeMember2023-01-012023-09-300000882095gild:OtherProductsAmBisomeMembercountry:US2022-01-012022-09-300000882095srt:EuropeMembergild:OtherProductsAmBisomeMember2022-01-012022-09-300000882095gild:OtherProductsAmBisomeMembergild:OtherInternationalMember2022-01-012022-09-300000882095gild:OtherProductsAmBisomeMember2022-01-012022-09-300000882095country:USgild:OtherProductsLetairisMember2023-01-012023-09-300000882095srt:EuropeMembergild:OtherProductsLetairisMember2023-01-012023-09-300000882095gild:OtherProductsLetairisMembergild:OtherInternationalMember2023-01-012023-09-300000882095gild:OtherProductsLetairisMember2023-01-012023-09-300000882095country:USgild:OtherProductsLetairisMember2022-01-012022-09-300000882095srt:EuropeMembergild:OtherProductsLetairisMember2022-01-012022-09-300000882095gild:OtherProductsLetairisMembergild:OtherInternationalMember2022-01-012022-09-300000882095gild:OtherProductsLetairisMember2022-01-012022-09-300000882095country:USgild:OtherProductsOtherMember2023-01-012023-09-300000882095srt:EuropeMembergild:OtherProductsOtherMember2023-01-012023-09-300000882095gild:OtherInternationalMembergild:OtherProductsOtherMember2023-01-012023-09-300000882095gild:OtherProductsOtherMember2023-01-012023-09-300000882095country:USgild:OtherProductsOtherMember2022-01-012022-09-300000882095srt:EuropeMembergild:OtherProductsOtherMember2022-01-012022-09-300000882095gild:OtherInternationalMembergild:OtherProductsOtherMember2022-01-012022-09-300000882095gild:OtherProductsOtherMember2022-01-012022-09-300000882095country:USgild:OtherProductsTotalOtherProductSalesMember2023-01-012023-09-300000882095srt:EuropeMembergild:OtherProductsTotalOtherProductSalesMember2023-01-012023-09-300000882095gild:OtherInternationalMembergild:OtherProductsTotalOtherProductSalesMember2023-01-012023-09-300000882095gild:OtherProductsTotalOtherProductSalesMember2023-01-012023-09-300000882095country:USgild:OtherProductsTotalOtherProductSalesMember2022-01-012022-09-300000882095srt:EuropeMembergild:OtherProductsTotalOtherProductSalesMember2022-01-012022-09-300000882095gild:OtherInternationalMembergild:OtherProductsTotalOtherProductSalesMember2022-01-012022-09-300000882095gild:OtherProductsTotalOtherProductSalesMember2022-01-012022-09-300000882095us-gaap:ProductMembercountry:US2023-01-012023-09-300000882095srt:EuropeMemberus-gaap:ProductMember2023-01-012023-09-300000882095us-gaap:ProductMembergild:OtherInternationalMember2023-01-012023-09-300000882095us-gaap:ProductMembercountry:US2022-01-012022-09-300000882095srt:EuropeMemberus-gaap:ProductMember2022-01-012022-09-300000882095us-gaap:ProductMembergild:OtherInternationalMember2022-01-012022-09-300000882095gild:RoyaltyContractAndOtherMembercountry:US2023-01-012023-09-300000882095srt:EuropeMembergild:RoyaltyContractAndOtherMember2023-01-012023-09-300000882095gild:RoyaltyContractAndOtherMembergild:OtherInternationalMember2023-01-012023-09-300000882095gild:RoyaltyContractAndOtherMembercountry:US2022-01-012022-09-300000882095srt:EuropeMembergild:RoyaltyContractAndOtherMember2022-01-012022-09-300000882095gild:RoyaltyContractAndOtherMembergild:OtherInternationalMember2022-01-012022-09-300000882095country:US2023-01-012023-09-300000882095srt:EuropeMember2023-01-012023-09-300000882095gild:OtherInternationalMember2023-01-012023-09-300000882095country:US2022-01-012022-09-300000882095srt:EuropeMember2022-01-012022-09-300000882095gild:OtherInternationalMember2022-01-012022-09-300000882095us-gaap:RevenueFromContractWithCustomerMembergild:CencoraIncMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-30xbrli:pure0000882095us-gaap:RevenueFromContractWithCustomerMembergild:CencoraIncMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300000882095us-gaap:RevenueFromContractWithCustomerMembergild:CencoraIncMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300000882095us-gaap:RevenueFromContractWithCustomerMembergild:CencoraIncMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300000882095us-gaap:RevenueFromContractWithCustomerMembergild:CardinalHealthIncMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300000882095us-gaap:RevenueFromContractWithCustomerMembergild:CardinalHealthIncMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300000882095us-gaap:RevenueFromContractWithCustomerMembergild:CardinalHealthIncMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300000882095us-gaap:RevenueFromContractWithCustomerMembergild:CardinalHealthIncMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300000882095us-gaap:RevenueFromContractWithCustomerMembergild:MckessonCorpMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300000882095us-gaap:RevenueFromContractWithCustomerMembergild:MckessonCorpMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300000882095us-gaap:RevenueFromContractWithCustomerMembergild:MckessonCorpMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300000882095us-gaap:RevenueFromContractWithCustomerMembergild:MckessonCorpMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300000882095us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-09-300000882095us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000882095us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000882095us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300000882095us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310000882095us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000882095us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000882095us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-09-300000882095us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-09-300000882095us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-09-300000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-09-300000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310000882095us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310000882095us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310000882095us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-09-300000882095us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000882095us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000882095us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300000882095us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310000882095us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000882095us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000882095us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMember2023-09-300000882095us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2023-09-300000882095us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2023-09-300000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:CertificatesOfDepositMember2023-09-300000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMember2022-12-310000882095us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2022-12-310000882095us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2022-12-310000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:CertificatesOfDepositMember2022-12-310000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2023-09-300000882095us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-09-300000882095us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-09-300000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:CorporateDebtSecuritiesMember2023-09-300000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2022-12-310000882095us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2022-12-310000882095us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2022-12-310000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:CorporateDebtSecuritiesMember2022-12-310000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Membergild:ResidentialMortgageAndAssetBackedSecuritiesMember2023-09-300000882095us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMembergild:ResidentialMortgageAndAssetBackedSecuritiesMember2023-09-300000882095us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMembergild:ResidentialMortgageAndAssetBackedSecuritiesMember2023-09-300000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMembergild:ResidentialMortgageAndAssetBackedSecuritiesMember2023-09-300000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Membergild:ResidentialMortgageAndAssetBackedSecuritiesMember2022-12-310000882095us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMembergild:ResidentialMortgageAndAssetBackedSecuritiesMember2022-12-310000882095us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMembergild:ResidentialMortgageAndAssetBackedSecuritiesMember2022-12-310000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMembergild:ResidentialMortgageAndAssetBackedSecuritiesMember2022-12-310000882095us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-09-300000882095us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000882095us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000882095us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300000882095us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310000882095us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000882095us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000882095us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310000882095gild:GalapagosMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-09-300000882095us-gaap:FairValueInputsLevel2Membergild:GalapagosMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000882095gild:GalapagosMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000882095gild:GalapagosMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300000882095gild:GalapagosMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310000882095us-gaap:FairValueInputsLevel2Membergild:GalapagosMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000882095gild:GalapagosMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000882095gild:GalapagosMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Membergild:ArcusBiosciencesIncMember2023-09-300000882095us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMembergild:ArcusBiosciencesIncMember2023-09-300000882095us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMembergild:ArcusBiosciencesIncMember2023-09-300000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMembergild:ArcusBiosciencesIncMember2023-09-300000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Membergild:ArcusBiosciencesIncMember2022-12-310000882095us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMembergild:ArcusBiosciencesIncMember2022-12-310000882095us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMembergild:ArcusBiosciencesIncMember2022-12-310000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMembergild:ArcusBiosciencesIncMember2022-12-310000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2023-09-300000882095us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2023-09-300000882095us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2023-09-300000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:EquitySecuritiesMember2023-09-300000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2022-12-310000882095us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2022-12-310000882095us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2022-12-310000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:EquitySecuritiesMember2022-12-310000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Membergild:DeferredCompensationPlanMember2023-09-300000882095us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMembergild:DeferredCompensationPlanMember2023-09-300000882095us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMembergild:DeferredCompensationPlanMember2023-09-300000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMembergild:DeferredCompensationPlanMember2023-09-300000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Membergild:DeferredCompensationPlanMember2022-12-310000882095us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMembergild:DeferredCompensationPlanMember2022-12-310000882095us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMembergild:DeferredCompensationPlanMember2022-12-310000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMembergild:DeferredCompensationPlanMember2022-12-310000882095us-gaap:FairValueMeasurementsRecurringMembergild:ForeignCurrencyDerivativeContractsMemberus-gaap:FairValueInputsLevel1Member2023-09-300000882095us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMembergild:ForeignCurrencyDerivativeContractsMember2023-09-300000882095us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMembergild:ForeignCurrencyDerivativeContractsMember2023-09-300000882095us-gaap:FairValueMeasurementsRecurringMembergild:ForeignCurrencyDerivativeContractsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300000882095us-gaap:FairValueMeasurementsRecurringMembergild:ForeignCurrencyDerivativeContractsMemberus-gaap:FairValueInputsLevel1Member2022-12-310000882095us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMembergild:ForeignCurrencyDerivativeContractsMember2022-12-310000882095us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMembergild:ForeignCurrencyDerivativeContractsMember2022-12-310000882095us-gaap:FairValueMeasurementsRecurringMembergild:ForeignCurrencyDerivativeContractsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-09-300000882095us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000882095us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310000882095us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000882095us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310000882095us-gaap:FairValueMeasurementsRecurringMembergild:MYRGmbHMemberus-gaap:FairValueInputsLevel1Member2023-09-300000882095us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMembergild:MYRGmbHMember2023-09-300000882095us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMembergild:MYRGmbHMember2023-09-300000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMembergild:MYRGmbHMember2023-09-300000882095us-gaap:FairValueMeasurementsRecurringMembergild:MYRGmbHMemberus-gaap:FairValueInputsLevel1Member2022-12-310000882095us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMembergild:MYRGmbHMember2022-12-310000882095us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMembergild:MYRGmbHMember2022-12-310000882095us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMembergild:MYRGmbHMember2022-12-310000882095srt:MaximumMember2023-09-300000882095us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300000882095us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310000882095us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2023-09-300000882095us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2022-12-310000882095srt:MaximumMembergild:MYRGmbHMember2021-03-31iso4217:EUR0000882095gild:ContingentConsiderationLiabilityMembergild:MYRGmbHMember2023-06-300000882095gild:ContingentConsiderationLiabilityMembergild:MYRGmbHMember2022-06-300000882095gild:ContingentConsiderationLiabilityMembergild:MYRGmbHMember2022-12-310000882095gild:ContingentConsiderationLiabilityMembergild:MYRGmbHMember2021-12-310000882095gild:ContingentConsiderationLiabilityMembergild:MYRGmbHMember2023-07-012023-09-300000882095gild:ContingentConsiderationLiabilityMembergild:MYRGmbHMember2022-07-012022-09-300000882095gild:ContingentConsiderationLiabilityMembergild:MYRGmbHMember2023-01-012023-09-300000882095gild:ContingentConsiderationLiabilityMembergild:MYRGmbHMember2022-01-012022-09-300000882095gild:ContingentConsiderationLiabilityMembergild:MYRGmbHMember2023-09-300000882095gild:ContingentConsiderationLiabilityMembergild:MYRGmbHMember2022-09-300000882095us-gaap:FairValueInputsLevel3Membergild:ImmunomedicsIncMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsNonrecurringMember2023-09-300000882095us-gaap:FairValueInputsLevel3Membergild:ImmunomedicsIncMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsNonrecurringMember2022-12-310000882095us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Membergild:ImmunomedicsIncMemberus-gaap:FairValueMeasurementsNonrecurringMember2023-09-300000882095us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Membergild:ImmunomedicsIncMemberus-gaap:FairValueMeasurementsNonrecurringMember2022-12-310000882095us-gaap:FairValueMeasurementsNonrecurringMembergild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member2022-01-012022-09-300000882095us-gaap:FairValueMeasurementsNonrecurringMembergild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member2023-01-012023-09-300000882095us-gaap:USTreasurySecuritiesMember2023-09-300000882095us-gaap:USTreasurySecuritiesMember2022-12-310000882095us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-09-300000882095us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310000882095us-gaap:ForeignGovernmentDebtSecuritiesMember2023-09-300000882095us-gaap:ForeignGovernmentDebtSecuritiesMember2022-12-310000882095us-gaap:CertificatesOfDepositMember2023-09-300000882095us-gaap:CertificatesOfDepositMember2022-12-310000882095us-gaap:CorporateDebtSecuritiesMember2023-09-300000882095us-gaap:CorporateDebtSecuritiesMember2022-12-310000882095gild:ResidentialMortgageAndAssetBackedSecuritiesMember2023-09-300000882095gild:ResidentialMortgageAndAssetBackedSecuritiesMember2022-12-310000882095us-gaap:CashAndCashEquivalentsMember2023-09-300000882095us-gaap:CashAndCashEquivalentsMember2022-12-310000882095gild:MarketableSecuritiesCurrentMember2023-09-300000882095gild:MarketableSecuritiesCurrentMember2022-12-310000882095gild:MarketableSecuritiesNoncurrentMember2023-09-300000882095gild:MarketableSecuritiesNoncurrentMember2022-12-310000882095us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-09-300000882095us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2022-12-310000882095us-gaap:OtherNoncurrentAssetsMember2023-09-300000882095us-gaap:OtherNoncurrentAssetsMember2022-12-310000882095us-gaap:EquitySecuritiesMember2023-09-300000882095us-gaap:EquitySecuritiesMember2022-12-310000882095gild:GileadFoundationMemberus-gaap:RelatedPartyMember2022-01-012022-09-300000882095us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-300000882095us-gaap:OtherCurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-300000882095us-gaap:OtherNoncurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-300000882095us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-300000882095us-gaap:DesignatedAsHedgingInstrumentMember2023-09-300000882095us-gaap:NondesignatedMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-09-300000882095us-gaap:NondesignatedMemberus-gaap:OtherCurrentLiabilitiesMember2023-09-300000882095us-gaap:NondesignatedMember2023-09-300000882095us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000882095us-gaap:OtherCurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000882095us-gaap:OtherNoncurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000882095us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000882095us-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000882095us-gaap:NondesignatedMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2022-12-310000882095us-gaap:NondesignatedMemberus-gaap:OtherCurrentLiabilitiesMember2022-12-310000882095us-gaap:NondesignatedMember2022-12-310000882095srt:MaximumMember2023-01-012023-09-300000882095gild:XinTheraIncMember2023-05-012023-05-310000882095gild:XinTheraIncMember2023-04-012023-06-300000882095gild:XinTheraIncMember2023-05-310000882095gild:TmunityTherapeuticsMember2023-02-222023-02-220000882095gild:TmunityTherapeuticsMember2023-01-012023-03-310000882095gild:TmunityTherapeuticsMember2023-09-300000882095gild:ArcellxIncMembergild:GlobalStrategicCollaborationAgreementMember2023-01-302023-01-300000882095gild:ArcellxIncMembergild:GlobalStrategicCollaborationAgreementMember2023-01-300000882095gild:ArcellxIncMembergild:ArcellxIncMembergild:GlobalStrategicCollaborationAgreementMember2023-01-300000882095gild:PionyrImmunotherapeuticsIncMember2020-06-190000882095gild:PionyrImmunotherapeuticsIncMember2023-01-012023-03-310000882095gild:TizonaTherapeuticsIncMember2020-07-310000882095gild:TizonaTherapeuticsIncMember2023-07-012023-09-300000882095gild:IntangibleAssetSofosbuvirMember2023-09-300000882095gild:IntangibleAssetSofosbuvirMember2022-12-310000882095gild:AxicabtageneciloleucelDLBCLMember2023-09-300000882095gild:AxicabtageneciloleucelDLBCLMember2022-12-310000882095gild:TrodelvyMember2023-09-300000882095gild:TrodelvyMember2022-12-310000882095gild:HepcludexMember2023-09-300000882095gild:HepcludexMember2022-12-310000882095us-gaap:OtherIntangibleAssetsMember2023-09-300000882095us-gaap:OtherIntangibleAssetsMember2022-12-310000882095us-gaap:InProcessResearchAndDevelopmentMember2023-09-300000882095us-gaap:InProcessResearchAndDevelopmentMember2022-12-310000882095us-gaap:InProcessResearchAndDevelopmentMember2023-03-310000882095gild:TrodelvyMember2023-03-310000882095gild:ImmunomedicsIncMembergild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member2020-12-310000882095gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member2022-03-310000882095gild:ImmunomedicsIncMemberus-gaap:MeasurementInputDiscountRateMembergild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member2022-03-310000882095us-gaap:FairValueMeasurementsNonrecurringMembergild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member2022-01-012022-03-310000882095us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000882095us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310000882095us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310000882095us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-09-300000882095us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-09-300000882095us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-09-300000882095us-gaap:AccumulatedTranslationAdjustmentMember2023-09-300000882095us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-09-300000882095us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-09-300000882095us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000882095us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310000882095us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000882095us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-09-300000882095us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-09-300000882095us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-09-300000882095us-gaap:AccumulatedTranslationAdjustmentMember2022-09-300000882095us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-09-300000882095us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-09-300000882095us-gaap:SeniorNotesMembergild:A250SeniorUnsecuredNotesDueSeptember2023Member2023-09-300000882095us-gaap:SeniorNotesMembergild:A250SeniorUnsecuredNotesDueSeptember2023Member2022-12-310000882095us-gaap:SeniorNotesMembergild:A075SeniorUnsecuredNotesDueSeptember2023Member2023-09-300000882095us-gaap:SeniorNotesMembergild:A075SeniorUnsecuredNotesDueSeptember2023Member2022-12-310000882095gild:A370SeniorUnsecuredNotesDueApril2024Memberus-gaap:SeniorNotesMember2023-09-300000882095gild:A370SeniorUnsecuredNotesDueApril2024Memberus-gaap:SeniorNotesMember2022-12-310000882095gild:A350SeniorUnsecuredNotesDueFebruary2025Memberus-gaap:SeniorNotesMember2023-09-300000882095gild:A350SeniorUnsecuredNotesDueFebruary2025Memberus-gaap:SeniorNotesMember2022-12-310000882095us-gaap:SeniorNotesMembergild:A365SeniorUnsecuredNotesDueMarch2026Member2023-09-300000882095us-gaap:SeniorNotesMembergild:A365SeniorUnsecuredNotesDueMarch2026Member2022-12-310000882095gild:A295SeniorUnsecuredNotesDueMarch2027Memberus-gaap:SeniorNotesMember2023-09-300000882095gild:A295SeniorUnsecuredNotesDueMarch2027Memberus-gaap:SeniorNotesMember2022-12-310000882095us-gaap:SeniorNotesMembergild:A120SeniorUnsecuredNotesDueOctober2027Member2023-09-300000882095us-gaap:SeniorNotesMembergild:A120SeniorUnsecuredNotesDueOctober2027Member2022-12-310000882095us-gaap:SeniorNotesMembergild:A165SeniorUnsecuredNotesDueOctober2030Member2023-09-300000882095us-gaap:SeniorNotesMembergild:A165SeniorUnsecuredNotesDueOctober2030Member2022-12-310000882095us-gaap:SeniorNotesMembergild:A525SeniorUnsecuredNotesDueOctober2033Member2023-09-300000882095us-gaap:SeniorNotesMembergild:A525SeniorUnsecuredNotesDueOctober2033Member2022-12-310000882095us-gaap:SeniorNotesMembergild:A460SeniorUnsecuredNotesDueSeptember2035Member2023-09-300000882095us-gaap:SeniorNotesMembergild:A460SeniorUnsecuredNotesDueSeptember2035Member2022-12-310000882095us-gaap:SeniorNotesMembergild:A400SeniorUnsecuredNotesDueSeptember2036Member2023-09-300000882095us-gaap:SeniorNotesMembergild:A400SeniorUnsecuredNotesDueSeptember2036Member2022-12-310000882095gild:A260SeniorUnsecuredNotesDueOctober2040Memberus-gaap:SeniorNotesMember2023-09-300000882095gild:A260SeniorUnsecuredNotesDueOctober2040Memberus-gaap:SeniorNotesMember2022-12-310000882095gild:A565SeniorUnsecuredNotesDueDecember2041Memberus-gaap:SeniorNotesMember2023-09-300000882095gild:A565SeniorUnsecuredNotesDueDecember2041Memberus-gaap:SeniorNotesMember2022-12-310000882095gild:A480SeniorUnsecuredNotesDueApril2044Memberus-gaap:SeniorNotesMember2023-09-300000882095gild:A480SeniorUnsecuredNotesDueApril2044Memberus-gaap:SeniorNotesMember2022-12-310000882095gild:A450SeniorUnsecuredNotesDueFebruary2045Memberus-gaap:SeniorNotesMember2023-09-300000882095gild:A450SeniorUnsecuredNotesDueFebruary2045Memberus-gaap:SeniorNotesMember2022-12-310000882095gild:A475SeniorUnsecuredNotesDueMarch2046Memberus-gaap:SeniorNotesMember2023-09-300000882095gild:A475SeniorUnsecuredNotesDueMarch2046Memberus-gaap:SeniorNotesMember2022-12-310000882095us-gaap:SeniorNotesMembergild:A415SeniorUnsecuredNotesDueMarch2047Member2023-09-300000882095us-gaap:SeniorNotesMembergild:A415SeniorUnsecuredNotesDueMarch2047Member2022-12-310000882095gild:A280SeniorUnsecuredNotesDueOctober2050Memberus-gaap:SeniorNotesMember2023-09-300000882095gild:A280SeniorUnsecuredNotesDueOctober2050Memberus-gaap:SeniorNotesMember2022-12-310000882095us-gaap:SeniorNotesMembergild:A555SeniorUnsecuredNotesDueOctober2053Member2023-09-300000882095us-gaap:SeniorNotesMembergild:A555SeniorUnsecuredNotesDueOctober2053Member2022-12-310000882095gild:SeniorNotesAndMediumTermNotesMember2023-09-300000882095gild:SeniorNotesAndMediumTermNotesMember2022-12-310000882095us-gaap:NotesPayableOtherPayablesMember2023-09-300000882095us-gaap:NotesPayableOtherPayablesMember2022-12-310000882095us-gaap:SeniorNotesMember2023-09-300000882095us-gaap:SeniorNotesMembergild:A555SeniorUnsecuredNotesDueOctober2053Member2023-09-012023-09-300000882095us-gaap:SeniorNotesMembergild:A525SeniorUnsecuredNotesDueOctober2033Member2023-09-012023-09-300000882095srt:MinimumMemberus-gaap:SeniorNotesMember2023-09-012023-09-300000882095srt:MaximumMemberus-gaap:SeniorNotesMember2023-09-012023-09-300000882095us-gaap:SeniorNotesMember2023-09-012023-09-300000882095gild:CreditFacilityDueJune2025Memberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2022-12-310000882095gild:CreditFacilityDueJune2025Memberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2023-09-300000882095us-gaap:SubsequentEventMember2023-07-012023-12-310000882095gild:PreExposureProphylaxisMember2020-04-30gild:agreement00008820952022-03-012022-03-31gild:patent00008820952023-05-012023-05-310000882095gild:ProductLiabilityMember2023-01-012023-09-30gild:lawsuitgild:plaintiff

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2023
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ________ to ________

Commission File No. 0-19731
 
GILEAD SCIENCES, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware94-3047598
(State or Other Jurisdiction of Incorporation or Organization)(IRS Employer Identification No.)
333 Lakeside Drive, Foster City, California 94404
(Address of principal executive offices) (Zip Code)
650-574-3000
(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value, $0.001 per shareGILDThe Nasdaq Global Select Market
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes x    No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x    No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer x Accelerated filer ¨ Non-accelerated filer ¨    
Smaller reporting company Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes     No x
Number of shares outstanding of the issuer’s common stock, par value $0.001 per share, as of October 31, 2023: 1,246,041,895



GILEAD SCIENCES, INC.
INDEX
We own or have rights to various trademarks, copyrights and trade names used in our business, including the following: GILEAD®, GILEAD SCIENCES®, KITE™, AMBISOME®, ATRIPLA®, BIKTARVY®, CAYSTON®, COMPLERA®, DESCOVY®, DESCOVY FOR PREP®, EMTRIVA®, EPCLUSA®, EVIPLERA®, GENVOYA®, HARVONI®, HEPCLUDEX®, HEPSERA®, JYSELECA®, LETAIRIS®, ODEFSEY®, RANEXA®, SOVALDI®, STRIBILD®, SUNLENCA®, TECARTUS®, TRODELVY®, TRUVADA®, TRUVADA FOR PREP®, TYBOST®, VEKLURY®, VEMLIDY®, VIREAD®, VOSEVI®, YESCARTA® and ZYDELIG®. Other trademarks are the property of their respective owners.
Certain amounts and percentages in this Quarterly Report on Form 10-Q may not sum or recalculate due to rounding.



This Quarterly Report on Form 10-Q, including Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations and Part II, Item 1A. Risk Factors, contains forward-looking statements regarding future events and our future results that are subject to the safe harbors created under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. Words such as “expect,” “anticipate,” “target,” “goal,” “project,” “hope,” “intend,” “plan,” “believe,” “seek,” “estimate,” “continue,” “may,” “could,” “should,” “might,” “forecast” and variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, any statements other than statements of historical fact are forward-looking statements, including statements regarding overall trends; operating cost and revenue trends; liquidity and capital needs; plans and expectations with respect to products, product candidates, corporate strategy, business and operations, financial projections and the use of capital; collaboration and licensing arrangements; patent protection and estimated loss of exclusivity for our products and product candidates; ongoing litigation and investigation matters; and other statements of expectations, beliefs, future plans and strategies, anticipated events or trends and similar expressions.
We have based these forward-looking statements on our current expectations about future events. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Our actual results may differ materially from those suggested by these forward-looking statements for various reasons, including those identified in Part II, Item 1A. Risk Factors. Given these risks and uncertainties, you are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements included in this report are made only as of the date hereof unless otherwise specified. Except as required under federal securities laws and the rules and regulations of U.S. Securities and Exchange Commission, we do not undertake, and specifically decline, any obligation to update any of these statements or to publicly announce the results of any revisions to any forward-looking statements after the distribution of this report, whether as a result of new information, future events, changes in assumptions or otherwise. In evaluating our business, you should carefully consider the risks described in Part II, Item 1A. Risk Factors of this Quarterly Report on Form 10-Q. Any of the risks contained herein could materially and adversely affect our business, results of operations and financial condition.
2


PART I.    FINANCIAL INFORMATION
Item 1.    CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
GILEAD SCIENCES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
(in millions, except per share amounts)September 30, 2023December 31, 2022
Assets  
Current assets:  
Cash and cash equivalents$5,705 $5,412 
Short-term marketable debt securities1,159 973 
Accounts receivable, net4,790 4,777 
Inventories1,663 1,507 
Prepaid and other current assets2,662 1,774 
Total current assets15,980 14,443 
Property, plant and equipment, net5,572 5,475 
Long-term marketable debt securities1,156 1,245 
Intangible assets, net27,152 28,894 
Goodwill8,314 8,314 
Other long-term assets4,200 4,800 
Total assets$62,373 $63,171 
Liabilities and Stockholders’ Equity  
Current liabilities:  
Accounts payable$586 $905 
Accrued rebates3,714 3,479 
Other current liabilities5,852 4,580 
Current portion of long-term debt and other obligations, net1,793 2,273 
Total current liabilities11,945 11,237 
Long-term debt, net23,189 22,957 
Long-term income taxes payable2,088 3,916 
Deferred tax liability1,984 2,673 
Other long-term obligations924 1,179 
Commitments and contingencies (Note 10)
Stockholders’ equity:  
Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding
  
Common stock, par value $0.001 per share; 5,600 shares authorized; 1,247 shares issued and outstanding
1 1 
Additional paid-in capital6,279 5,550 
Accumulated other comprehensive income31 2 
Retained earnings16,002 15,687 
Total Gilead stockholders’ equity22,314 21,240 
Noncontrolling interest(72)(31)
Total stockholders’ equity22,242 21,209 
Total liabilities and stockholders’ equity$62,373 $63,171 



See accompanying notes.
3


GILEAD SCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
 Three Months EndedNine Months Ended
September 30,September 30,
(in millions, except per share amounts)2023202220232022
Revenues:
Product sales$6,994 $6,978 $19,864 $19,650 
Royalty, contract and other revenues56 64 138 242 
Total revenues7,051 7,042 20,002 19,892 
Costs and expenses:
Cost of goods sold1,565 1,395 4,408 4,261 
Research and development expenses1,457 1,149 4,310 3,429 
Acquired in-process research and development expenses91 448 808 786 
In-process research and development impairment   2,700 
Selling, general and administrative expenses1,315 1,213 4,482 3,653 
Total costs and expenses4,428 4,205 14,009 14,829 
Operating income2,623 2,837 5,993 5,063 
Interest expense(232)(229)(692)(709)
Other income (expense), net(72)(176)(95)(571)
Income before income taxes2,318 2,432 5,206 3,783 
Income tax expense(146)(646)(1,010)(850)
Net income2,172 1,786 4,196 2,933 
Net loss attributable to noncontrolling interest8 3 40 19 
Net income attributable to Gilead$2,180 $1,789 $4,236 $2,952 
Basic earnings per share attributable to Gilead$1.75 $1.43 $3.39 $2.35 
Shares used in basic earnings per share attributable to Gilead calculation1,248 1,255 1,249 1,255 
Diluted earnings per share attributable to Gilead$1.73 $1.42 $3.37 $2.34 
Shares used in diluted earnings per share attributable to Gilead calculation1,257 1,261 1,259 1,261 





















See accompanying notes.
4


GILEAD SCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(unaudited)
Three Months EndedNine Months Ended
September 30,September 30,
(in millions)2023202220232022
Net income$2,172 $1,786 $4,196 $2,933 
Other comprehensive income, net:
Net foreign currency translation loss(35)(81)(3)(102)
Available-for-sale debt securities:
Net unrealized gain (loss), net of tax impact of $0, $0, $0 and $0, respectively
4 (7)10 (38)
Reclassifications to net income, net of tax impact of $0, $0, $0 and $0, respectively
  2 1 
Net change5 (7)11 (37)
Cash flow hedges:
Net unrealized gain, net of tax impact of $9, $21, $9 and $37, respectively
66 140 65 254 
Reclassifications to net income, net of tax impact of $2, $7, $6 and $15, respectively
(14)(41)(44)(100)
Net change51 99 21 154 
Other comprehensive income, net21 11 30 15 
Comprehensive income, net2,193 1,797 4,226 2,948 
Comprehensive loss attributable to noncontrolling interest, net8 3 40 19 
Comprehensive income attributable to Gilead, net$2,201 $1,800 $4,265 $2,967 





























See accompanying notes.
5


GILEAD SCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(unaudited)
Three Months Ended September 30, 2023
(in millions, except per share amounts)Gilead Stockholders’ Equity Noncontrolling
Interest
Total
Stockholders’
Equity
Common Stock 
Additional
Paid-In
Capital
Accumulated Other Comprehensive IncomeRetained
Earnings
SharesAmount
Balance as of June 30, 20231,247 $1 $6,008 $10 $15,138 $(64)$21,094 
Net income (loss)— — — — 2,180 (8)2,172 
Other comprehensive income, net— — — 21 — — 21 
Issuances under employee stock purchase plan1 — 62 — — — 62 
Issuances under equity incentive plans4 — 21 — — — 21 
Stock-based compensation— — 202 — — — 202 
Repurchases of common stock under repurchase programs ($77.08 average price per share)
(4)— (14)— (286)— (300)
Repurchases of common stock for employee tax withholding under equity incentive plans and other(1)— — — (77)— (77)
Dividends declared ($0.75 per share)
— — — — (953)— (953)
Balance as of September 30, 20231,247 $1 $6,279 $31 $16,002 $(72)$22,242 
Nine Months Ended September 30, 2023
(in millions, except per share amounts)Gilead Stockholders’ Equity Noncontrolling
Interest
Total
Stockholders’
Equity
Common Stock 
Additional
Paid-In
Capital
Accumulated Other Comprehensive IncomeRetained
Earnings
SharesAmount
Balance as of December 31, 20221,247 $1 $5,550 $2 $15,687 $(31)$21,209 
Net income (loss)— — — — 4,236 (40)4,196 
Other comprehensive income, net— — — 30 — — 30 
Issuances under employee stock purchase plan2 — 129 — — — 129 
Issuances under equity incentive plans11 — 71 — — — 71 
Stock-based compensation— — 566 — — — 566 
Repurchases of common stock under repurchase programs ($79.92 average price per share)
(11)— (38)— (812)— (850)
Repurchases of common stock for employee tax withholding under equity incentive plans and other(3)— — — (245)— (245)
Dividends declared ($2.25 per share)
— — — — (2,864)— (2,864)
Balance as of September 30, 20231,247 $1 $6,279 $31 $16,002 $(72)$22,242 












See accompanying notes.
6


Three Months Ended September 30, 2022
(in millions, except per share amounts)Gilead Stockholders’ Equity Noncontrolling
Interest
Total
Stockholders’
Equity
Common Stock 
Additional
Paid-In
Capital
Accumulated Other Comprehensive IncomeRetained
Earnings
SharesAmount
Balance as of June 30, 20221,254 $1 $5,031 $87 $15,117 $(21)$20,215 
Net income (loss)— — — — 1,789 (3)1,786 
Other comprehensive income, net— — — 11 — — 11 
Issuances under employee stock purchase plan2 — 30 — — — 30 
Issuances under equity incentive plans2 — 6 — — — 6 
Stock-based compensation— — 170 — — — 170 
Repurchases of common stock under repurchase programs ($63.10 average price per share)
(3)— (11)— (171)— (182)
Repurchases of common stock for employee tax withholding under equity incentive plans(1)— — — (46)— (46)
Dividends declared ($0.73 per share)
— — — — (933)— (933)
Balance as of September 30, 20221,254 $1 $5,226 $98 $15,756 $(24)$21,057 

Nine Months Ended September 30, 2022
(in millions, except per share amounts)Gilead Stockholders’ Equity Noncontrolling
Interest
Total
Stockholders’
Equity
Common Stock 
Additional
Paid-In
Capital
Accumulated Other Comprehensive IncomeRetained
Earnings
SharesAmount
Balance as of December 31, 20211,254 $1 $4,661 $83 $16,324 $(5)$21,064 
Net income (loss)— — — — 2,952 (19)2,933 
Other comprehensive income, net— — — 15 — — 15 
Issuances under employee stock purchase plan3 — 103 — — — 103 
Issuances under equity incentive plans9 — 30 — — — 30 
Stock-based compensation— — 465 — — — 465 
Repurchases of common stock under repurchase programs ($63.34 average price per share)
(10)— (33)— (572)— (605)
Repurchases of common stock for employee tax withholding under equity incentive plans(2)— — — (151)— (151)
Dividends declared ($2.19 per share)
— — — — (2,797)— (2,797)
Balance as of September 30, 20221,254 $1 $5,226 $98 $15,756 $(24)$21,057 
















See accompanying notes.
7


GILEAD SCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
Nine Months Ended
September 30,
(in millions)20232022
Operating Activities:
Net income$4,196 $2,933 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation expense263 240 
Amortization expense1,742 1,335 
Stock-based compensation expense565 463 
Acquired in-process research and development expenses808 786 
In-process research and development impairment 2,700 
Deferred income taxes(592)(1,214)
Net loss from equity securities356 596 
Other260 546 
Changes in operating assets and liabilities:
Accounts receivable, net(63)(125)
Inventories(535)(34)
Prepaid expenses and other71 (69)
Accounts payable(304)(38)
Income tax assets and liabilities, net(1,070)(483)
Accrued and other liabilities141 (1,131)
Net cash provided by operating activities5,837 6,505 
Investing Activities:
Purchases of marketable debt securities(1,474)(1,398)
Proceeds from sales of marketable debt securities412 370 
Proceeds from maturities of marketable debt securities985 1,232 
Acquisitions, including in-process research and development, net of cash acquired(873)(1,579)
Purchases of equity securities(218)(166)
Capital expenditures(370)(547)
Other (3)
Net cash used in investing activities(1,538)(2,091)
Financing Activities:
Proceeds from debt financing, net of issuance costs1,979  
Proceeds from issuances of common stock206 133 
Repurchases of common stock under repurchase programs(850)(604)
Repayments of debt and other obligations(2,250)(1,500)
Payments of dividends(2,866)(2,794)
Other(245)(150)
Net cash used in financing activities(4,026)(4,915)
Effect of exchange rate changes on cash and cash equivalents20 (138)
Net change in cash and cash equivalents293 (639)
Cash and cash equivalents at beginning of period5,412 5,338 
Cash and cash equivalents at end of period$5,705 $4,699 



See accompanying notes.
8


GILEAD SCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
1.    ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The accompanying Condensed Consolidated Financial Statements and related Notes to Condensed Consolidated Financial Statements of Gilead Sciences, Inc. (“Gilead,” “we,” “our” or “us”) should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December 31, 2022, included in our Annual Report on Form 10-K filed with U.S. Securities and Exchange Commission. There have been no material changes to our organization or summary of significant accounting policies as disclosed in that filing. Beginning in the first quarter of 2023, we reclassified changes in income taxes prepaid and receivable from Prepaid expenses and other to combine them with changes in income taxes payable as Income tax assets and liabilities, net within Operating Activities on our Condensed Consolidated Statements of Cash Flows. We believe this presentation assists users of the financial statements to better understand cash flow movements. Prior periods have been revised to reflect this change, resulting in a reclassification of $81 million from Prepaid expenses and other for the nine months ended September 30, 2022.
These interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and include all adjustments consisting of normal recurring adjustments that the management of Gilead believes are necessary for a fair presentation of the periods presented and are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period. Certain amounts and percentages in these Condensed Consolidated Financial Statements and accompanying notes may not sum or recalculate due to rounding.
9


2.    REVENUES
Disaggregation of Revenues
The following table summarizes our Total revenues:
Three Months Ended September 30, 2023Three Months Ended September 30, 2022
(in millions)U.S.EuropeOther InternationalTotalU.S.EuropeOther InternationalTotal
Product sales:
HIV
Biktarvy$2,504 $313 $268 $3,085 $2,286 $278 $201 $2,766 
Complera/Eviplera13 18 3 34 20 21 3 43 
Descovy460 25 26 511 444 28 28 500 
Genvoya433 47 23 503 502 71 27 600 
Odefsey257 74 11 343 276 86 12 374 
Stribild18 5 2 25 22 7 3 32 
Truvada15 3 4 22 24 3 2 30 
Revenue share - Symtuza(1)
96 32 3 131 85 40 4 130 
Other HIV(2)
10 3  13 1 6 5 12 
Total HIV3,807 519 341 4,667 3,661 541 285 4,487 
Oncology
Cell Therapy
Tecartus64 27 4 96 60 20 1 81 
Yescarta197 154 40 391 210 91 16 317 
Total Cell Therapy261 181 45 486 270 111 17 398 
Trodelvy201 62 21 283 139 38 3 180 
Total Oncology462 243 65 769 409 149 20 578 
Liver Disease
Chronic hepatitis C virus (“HCV”)
Ledipasvir/Sofosbuvir(3)
17 2 4 23 8 5 12 25 
Sofosbuvir/Velpatasvir(4)
215 76 85 377 241 131 84 455 
Other HCV(5)
28 7 3 38 34 7 2 44